Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$18.89M-$18.89MN/M vs Q1 2025 EPS Diluted-$0.25-$0.25N/M vs Q1 2025 Operating Income-$22,186,000N/M Operating Cash Flow-$18,750,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,758,000N/M ended Mar 31, 2026 · filed Apr 27, 2026 · 27 d after period end